Background:
Obesity is a growing epidemic in Saudi Arabia, and Semaglutide has emerged as a promising pharmacotherapeutic option for weight management in obese patients. This study aims to assess public knowledge about Ozempic (semaglutide) use, safety, and adverse drug reactions in Saudi Arabia.
Methods:
We conducted a cross-sectional survey to collect data among the adult population in Saudi Arabia. Statistical tests of significance, including the chi-squared test and Spearman's rho correlation test, were employed to examine differences between groups and assess correlations between variables.
Results:
Of the 739 participants, 50.7% were females, and most participants had a bachelor’s degree level of education. Study respondents reported that they had heard of Ozempic, but only 244 (58%) knew its indication (Type 2 DM). The analysis showed that good knowledge was observed among the 31–40 and 18–30 age groups compared to other age groups (p = 0.020); no other sociodemographic variables showed a significant association with the knowledge level (p > 0.05).The questionnaire was distributed to a representative sample with a minimum of 385 participants among the Saudi population, with a 95% confidence level and a margin of error of 5%, through online platforms. Data were collected and analyzed using descriptive and inferential statistical methods.
Conclusion:
Semaglutide is a valuable medication for the treatment of type 2 diabetes and, under appropriate circumstances, for weight loss management. The study showed that the majority of the participants used it for weight loss management, and their awareness regarding its indications, contraindications, and adverse effects was not adequate.
Key words: Obesity management, diabetes mellitus, Saudi Arabia, GLP-1, semaglutide, ozempic.
|
